CAR-T is having a moment. Novartis (NVS) won the first Food and Drug Administration approval in August for this class of personalized cancer treatments, beating rivals in the race to sell a therapy that is custom-made with individual patients’ cells.

Manufacturing such treatments presents a challenge radically different from what most biopharma companies face in making standard drugs. Treating one patient with CAR-T — sometimes called a “living drug” — requires cells to be extracted, purified, modified to become cancer killers, and then returned to that patient.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • What are your thoughts on BLFS, seems like they have made the biggest gains for servicing the space over the last year.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy